These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam. Sader HS, Tosin I, Sejas L, Miranda E. Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842 [Abstract] [Full Text] [Related]
4. Ampicillin-sulbactam: an update on the use of parenteral and oral forms in bacterial infections. Betrosian AP, Douzinas EE. Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1099-112. PubMed ID: 19621991 [Abstract] [Full Text] [Related]
5. [A combination of ampicillin and sulbactam: effect on aerobic and anaerobic gram-negative bacteria]. González C, García A, Urrea R, del Solar E, Bello H, Zemelman R. Rev Med Chil; 1990 May; 118(5):548-54. PubMed ID: 2293275 [Abstract] [Full Text] [Related]
6. Inactivation of beta-lactamases by sulbactam and enhanced clinical activity due to target-site binding of the combination of sulbactam and ampicillin. Yokota T. APMIS Suppl; 1989 May; 5():9-16. PubMed ID: 2786726 [Abstract] [Full Text] [Related]
15. Rational antibiotic therapy and the position of ampicillin/sulbactam. Lode HM. Int J Antimicrob Agents; 2008 Jul; 32(1):10-28. PubMed ID: 18539004 [Abstract] [Full Text] [Related]
17. [Stability of beta-lactamase inhibitors and beta-lactam antibiotics in parenteral formulations as well as in body fluids and tissue homogenates. Comparison of sulbactam, clavulanic acid, ampicillin and amoxicillin]. Wildfeuer A, Räder K. Arzneimittelforschung; 1991 Jan; 41(1):70-3. PubMed ID: 2049115 [Abstract] [Full Text] [Related]
18. Parenteral beta-lactamase inhibitor combinations for clinical use. Manzella JP. Am Fam Physician; 1995 May 15; 51(7):1695-8. PubMed ID: 7754928 [Abstract] [Full Text] [Related]